Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardiology and Angiology 2021 February;69(1) > Minerva Cardiology and Angiology 2021 February;69(1):38-44

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Cardiology and Angiology 2021 February;69(1):38-44

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Balloon catheters and stents with paclitaxel: are they really dangerous? A review and update

Frantisek STANEK

Department of Cardiology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic


PDF


The aim of this review is to summarize and update current research concerning the safety of drug-coated balloons (DCBs) and drug-eluting stents (DESs) with paclitaxel (PTX) in peripheral arteries. The data from the large randomized controlled trials showed evidence of the superiority of DCBs over plain balloon angioplasty concerning efficacy. Also, the safety parameters between the two groups did not differ. However, two meta-analyses identifying an increased late mortality risk after using PTX technologies were published only a short time ago. In contradiction, a lot of following studies (meta-analyses, real-world analysis, retrospective review) published in 2019 and 2020, did not confirm any significant difference in all-cause death between PTX and no-PTX cohorts. The safety of PTX technologies still represents the most serious and controversial issue in peripheral interventions. Until it is definitively solved further research must continue. In daily practice, recommendations for the use of PTX products include the treatment of restenosis after percutaneous transluminal angioplasty (PTA) (not of de novo lesions), the maintenance of patency of bypasses, and angioplasty for limb salvage. In heavily calcified lesions, a prior debulking with atherectomy is suitable. Generally, the risks and benefits of the application of PTX devices should be considered in every single patient.


KEY WORDS: Drugs-eluting stents; Safety; Paclitaxel

inizio pagina